Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation

Pharmacotherapy

Volumn 32, Issue 12, 2012, Pages 1061-1069

  Eyler, Rachel F ^a,b   Heung, Michael ^b,c,d   Pleva, Melissa ^a,c   Sowinski, Kevin M ^b,e   Park, Pauline K ^d   Napolitano, Lena M ^c,d   Mueller, Bruce A ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Renal Replacement Therapy Kinetics Study Group   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

Continuous venovenous hemodialysis; Critical illness; CVVHD; ECMO; Extracorporeal membrane oxygenation; Oseltamivir; Oseltamivir carboxylate; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS HEMODIALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG HALF LIFE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NASOENTERIC DRUG ADINISTRATION; NASOGASTRIC DRUG ADMINISTRATION; OPEN STUDY; PRESCRIPTION; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNIVERSITY HOSPITAL; URINALYSIS;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS;

EID: 84871573013     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1151     Document Type: Article

References (32)

1. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-44
2. Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. Crit Care Med 2010;38 (suppl):e43-51
3. World Health Organization. WHO guidelines for clinical management of human infection with pandemic (H1N1) 2009; revised guidance, 2009. Available from http://www.who.int/csr/ resources/publications/swineflu/clinical- management/en/index. htmL. Accessed January 18, 2011
4. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37:471-84 (Pubitemid 30032251)
5. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005;60:265-75 (Pubitemid 41224134)
6. Spriet I, Annaert P, Meersseman P, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 2009;63:767-70
7. Green MD, Nettey H, Wirtz RA. Determination of oseltamivir quality by colorimetric and liquid chromatographic methods. Emerg Infect Dis 2008;14:552-6 (Pubitemid 351520855)
8. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010;182:357-63
9. Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004;61:134-43 (Pubitemid 38219910)
10. Vilay AM, Grio M, DePestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011;39:19-25
11. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, Inc., 1982
12. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1979;68:1071-4 (Pubitemid 10099391)
13. Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multipledose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003;47:2256-63 (Pubitemid 36753581)
14. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012;40:1523-8
15. Barquist ES, Gomez-Fein E, Block EF, Collin G, Alzamel H, Martinez O. Bioavailability of oral fluconazole in critically ill abdominal trauma patients with and without abdominal wall closure: a randomized crossover clinical trial. J Trauma 2007;63:159-63 (Pubitemid 47057579)
16. Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009;35:717-21
17. Eyler RF, Mueller BA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol 2011;7:226-35
18. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. [published online ahead of print April 18, 2012]. J Crit Care. Available from http://www.jccjournal.org/ article/ S0883-9441%2812%2900092-5/abstract
19. Genentech USA, Inc. Tamiflu (oseltamivir) prescribing information. South San Francisco, CA; 2011
20. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 2009;77:238-47
21. Yang J, Shi D, Yang D, Song X, Yan B. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol 2007;72:686-94 (Pubitemid 47347303)
22. Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006;319:1477-84
23. Zhu HJ, Appel DI, Peterson YK, Wang Z, Markowitz JS. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology 2010;270:59-65
24. Fleming CD, Bencharit S, Edwards CC, et al. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol 2005;352:165-77 (Pubitemid 41207447)
25. Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, Yokoi T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos 2010;38:2173-8
26. Zhang J, Burnell JC, Dumaual N, Bosron WF. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther 1999;290:314-38
27. Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008;52:3013-21
28. Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007;47:689- 96 (Pubitemid 46800424)
29. Wildschut ED, de Hoog M, Ahsman MJ, Tibboel D, Osterhaus AD, Fraaij PL. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One 2010;5: e10938
30. Lemaitre F, Luyt CE, Roullet-Renoleau F, et al. Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation. Intensive Care Med 2010;36:1273-4
31. Gubavera L, Okomo-Adhiambo M, Deyde V, et al. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR 2009;58:433-5
32. Wattanagoon Y, Stepniewska K, Lindegårdh N, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009;53:945-52